Codon-specific KRAS mutations predict survival in advanced pancreatic cancer

Background: How distinct KRAS alterations in pancreatic adenocarcinoma (PDAC) influence tumor initiation and outcomes remains unclear. Moreover, KRAS is now partly targetable with novel specific inhibitors targeting KRASG12 (G12C or G12D), but specific outcomes of these subgroups of patients is poor...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	A. Boilève, A. Rousseau, M. Hilmi, A. Tarabay, J.R.R. Mathieu, J. Cartry, S. Bedja, N. Goudarzi, C. Nicotra, M. Ngo-Camus, V. Boige, M. Valéry, T. Pudlarz, M.-A. Bani, P. Dartigues, L. Tselikas, A. Italiano, S. Cosconea, M. Gelli, E. Fernandez-de-Sevilla, D. Malka, M. Annereau, F. Jaulin, C. Smolenschi, A. Hollebecque, M. Ducreux
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2024-03-01
Serier:	ESMO Gastrointestinal Oncology
Fag:	precision medicine KRAS pancreatic cancer
Online adgang:	http://www.sciencedirect.com/science/article/pii/S2949819823000456
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!